Agios Pharmaceuticals Inc AGIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes
-
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
-
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
-
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
-
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
-
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
-
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
-
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 75.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 386
- Website
- https://www.agios.com
Comparables
Valuation
|
Metric
|
AGIO
|
RCKT
|
SYRE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 2.58 |
Price/Book Value | 3.60 | 4.01 | 6.43 |
Price/Sales | 75.06 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AGIO
RCKT
SYRE
Financial Strength
|
Metric
|
AGIO
|
RCKT
|
SYRE
|
|---|---|---|---|
Quick Ratio | 9.16 | 7.42 | 19.26 |
Current Ratio | 10.09 | 7.79 | 19.70 |
Interest Coverage | — | −143.43 | — |
Quick Ratio
AGIO
RCKT
SYRE
Profitability
|
Metric
|
AGIO
|
RCKT
|
SYRE
|
|---|---|---|---|
Return on Assets (Normalized) | −34.45% | −41.09% | −42.01% |
Return on Equity (Normalized) | −39.42% | −46.72% | — |
Return on Invested Capital (Normalized) | −40.06% | −47.69% | −298.64% |
Return on Assets
AGIO
RCKT
SYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ypqdrlbqz | Zvm | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Clcdftxl | Gkfyd | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dpfxzrgj | Zxszflt | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zxtrptlj | Ctjvtg | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Zjvmcntv | Vsz | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Mbxqxhw | Jrbgs | $28.3 Bil | |||
| Moderna Inc
MRNA
| Rddczkvmd | Llvfq | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Gwwsqvl | Nth | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wvtpglpch | Bsmnjg | $13.3 Bil | |||
| Incyte Corp
INCY
| Gysfczbyw | Myjkfv | $13.0 Bil |
United States